Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Inclusion Criteria: * Provide written, informed consent prior to all study-related procedures and agree to undergo all study procedures * Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive * Newly diagnosed pulmonary TB * Rifampicin susceptible pulmonary TB as determined by molecular testing * Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 ml or more) * Spirometry performed during screening with a FEV1 of ≥ 40% * Be of non-childbearing potential or willing to use effective methods of contraception Exclusion Criteria: * HIV positive AND CD4 \< 350 cells/mm3 OR are receiving antiviral therapy (ART) * Methaemoglobin saturation (SpMet) \>3% * Female participant who is pregnant or breast-feeding * Participants planning to conceive a child within the anticipated period of study participation and for at least 90 days after the last dose of IMP in the study * Participation in other clinical studies with investigational agents within 8 weeks prior to screening * Treatment received for this episode of TB with any drug active against M.tb * Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening. * Treatment with nitric oxide and other nitric oxide donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening